Procysteine

Procysteine

SCHEMBL83023

O=C1NC(C(=O)O)CS1

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Procysteine SCHEMBL9139321 1.00 HTT (0.53) —
Procysteine SCHEMBL1134004 1.00 — —
Procysteine SCHEMBL352387 1.00 — —
Procysteine SCHEMBL10623235 0.98 HTT (0.52) —
Procysteine SCHEMBL4164380 0.98 HTT (0.52) —
Procysteine SCHEMBL8428864 0.98 HTT (0.52) —
Procysteine SCHEMBL1150486 0.84 HTT (0.45) —
Procysteine SCHEMBL20822405 0.84 HTT (0.45) —
Procysteine SCHEMBL8040939 0.83 HTT (0.41) —
Procysteine SCHEMBL1681501 0.80 PTGS1 (0.47) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2633 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 — — EP claimed
EP-4632063-A2 COPPER LOSS MITIGATION GENENTECH, INC. (US) 2025-10-15 — — EP claimed
US-12428447-B2 Peptide-based non-proteinaceous cargo delivery FELDAN BIO INC. (CA) 2025-09-30 — — US claimed
EP-4136211-B1 COPPER LOSS MITIGATION GENENTECH INC (US) 2025-07-09 — — EP claimed
US-20250171739-A1 PROCESS FOR GENERATING THERAPEUTIC COMPOSITIONS OF ENGINEERED CELLS JUNO THERAPEUTICS, INC. (US) 2025-05-29 — — US claimed
US-12258580-B2 Process for generating therapeutic compositions of engineered cells JUNO THERAPEUTICS, INC. (US) 2025-03-25 — — US claimed
EP-4512823-A2 PROCESS FOR GENERATING THERAPEUTIC COMPOSITIONS OF ENGINEERED CELLS Juno Therapeutics, Inc. (US) 2025-02-26 — — EP claimed
EP-4468884-A1 LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT Amarin Pharmaceuticals Ireland Limited (IE) 2024-12-04 — — EP claimed
CN-118714935-A Lymphoreleased fatty acid compositions and their use for lymphatic incorporation and systemic disease treatment 阿马里纳药物爱尔兰有限公司 2024-09-27 — — CN claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 — — WO claimed
EP-0494405-A2 Use of thiazolidine-4-carboxylate derivatives for the treatment of pulmonary diseases Transcend Therapeutics, Inc. (US) 1992-07-15 — — EP claimed
US-5095027-A Antiischemic CLINTEC NUTRITION CO. (US) 1992-03-10 — — US claimed
WO-1991016820-A1 PHOTODYNAMIC PLANT DEFOLIANTS AND CHLOROPHYLL BIOSYNTHESIS MODULATORS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 1991-11-14 — — WO claimed
US-4665082-A ENZYMATIC HYDROLYSIS OF L-2-OXOTHIAZOLIDINE-4-CARBOXYLATE CORNELL RESEARCH FOUNDATION (US) 1987-05-12 — — US claimed
US-4647571-A 2-OXOTHIAZOLIDINE-4-CARBOXYLATE CORNELL RESEARCH FOUNDATION (US) 1987-03-03 — — US claimed
EP-0057942-B1 CYSTEINE DELIVERY SYSTEM Cornell Research Foundation (US) 1985-09-11 — — EP claimed
US-4438124-A ADMINISTERING L-2-OXOTHIAZOLIDINE-4-CARBOXYLATE CORNELL RESEARCH FOUNDATION, INC. (US) 1984-03-20 — — US claimed
US-4434158-A INCREASING GLUTATHIONE LEVELS CORNELL RESEARCH FOUNDATION (US) 1984-02-28 — — US claimed
EP-0057942-A2 Cysteine delivery system Cornell Research Foundation (US) 1982-08-18 — — EP claimed
US-4335210-A ENZYMATIC HYDROLYSI OF 2-OXOTHIAZOLIDINE-4-CARBOXYLATE CORNELL RESEARCH FOUNDATION (US) 1982-06-15 — — US claimed
Send feedback